Halberd News

Press releases and updates on our medical breakthroughs.

Jul 16 2020

Halberd Advances the Treatment of COVID-19 Utilizing Laser Technology

By |2020-07-21T11:29:21-04:00July 16th, 2020|Featured, Investor News|0 Comments

Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and ...

Jul 13 2020

Halberd Corp – Update July 13, 2020 – Addresses Certain Issues

By |2020-07-12T21:15:03-04:00July 13th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 13, 2020 – Halberd Corp. (OTC PINK: "HALB") today issued a statement to clarify certain items within its charter regarding allowable debt.  There have been inaccurate rumors that have put the company in a negative light.  One of these is that the company intends to take on convertible debt. Nothing could ...

Jul 7 2020

COVID-19 Cytokine Storm, Coronavirus’ Deadliest Stage – Halberd’s US Patent Pending Treatment Now Explained!

By |2020-07-06T19:47:51-04:00July 7th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on ...

Jul 1 2020

Halberd Establishes UK Subsidiary

By |2020-07-01T10:06:25-04:00July 1st, 2020|Featured, News|0 Comments

Jackson Center, PA, July 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets.  The subsidiary is Halberd Corporation UK, Ltd. William A. Hartman, Chairman, President & CEO of Halberd, stated, “This is the first step in our overall ...

Jun 29 2020

Halberd Method for Treating and Curing the COVID-19 Infection Explained

By |2020-06-28T19:55:51-04:00June 29th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, June 29, 2020 – Halberd Corporation (OTC-PINK: "HALB") today unveils the first of three (3) COVID -19 (Coronavirus) patent pending treatment methods -- the first titled, “Method for Treating and Curing Covid-19 Infection” -- filed with the U.S. Patent and Trademark Office on March 16, 2020.  Halberd holds exclusive worldwide license to ...

Jun 22 2020

NFL Retired Players Association’s Chief Medical Officer Joins Halberd Corporation to Lead COVID-19 Efforts

By |2020-06-21T20:27:29-04:00June 22nd, 2020|Featured, News, Technology|0 Comments

Effective Immediately! Jackson Center, PA, June 22, 2020 – Halberd Corporation (OTC Pink: HALB) announced the appointment of Dr. Patricio F. Reyes to the position of Chief Technical Officer effective immediately.  He will report to Halberd’s new Chairman, President and CEO, William A. Hartman and is currently the Chief Medical Officer of the NFL’s Retired ...

Jun 15 2020

Halberd Designated “Pink Current Information” by OTC and Continues Technology Progress

By |2020-06-21T04:55:39-04:00June 15th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, June 15, 2020 –Halberd Corporation (OTC Pink: HALB) announced that OTC Markets has completed its background investigation and analysis of all filings by Halberd Corporation and now designates Halberd Corporation as "Pink Current Information". William A. Hartman, newly appointed Chairman, President and CEO explains, “Now that Halberd has been designated by OTC ...

Jun 9 2020

Halberd Corporation Appoints Dr. Patricio Reyes to Scientific Advisory Board

By |2020-06-21T23:04:50-04:00June 9th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, June 9, 2020 – Halberd Corporation (OTC Pink: HALB) announced the appointment of Dr. Patricio F. Reyes to its Scientific Advisory Board effective immediately  He will report to Halberd’s Chairman, President and CEO, William A. Hartman. Dr. Reyes, MD, FAAN, a board certified neurologist and neuropathologist, is a Board Member of the ...

Apr 8 2020

Premier Biomedical, Halberd and Gold River Agree to Work Jointly to Develop Premier’s Patented Extracorporeal Technology on COVID-19 Treatment And Proprietary Anti-Addiction PatchTM

By |2020-04-08T21:24:15-04:00April 8th, 2020|News|Comments Off on Premier Biomedical, Halberd and Gold River Agree to Work Jointly to Develop Premier’s Patented Extracorporeal Technology on COVID-19 Treatment And Proprietary Anti-Addiction PatchTM

Jackson Center, PA, April 8, 2020 – Premier Biomedical, Inc. (OTC-PINK: “BIEI“), Halberd Corporation (OTC-PINK: HALB) and Gold River Productions Inc. (OTC-PINK: GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction PatchTM. The Joint Venture on Covid-19 treatment starts with Dr. Mitchell ...

Apr 6 2020

Halberd Announces Agreement To Retire 192,000,000 Outstanding Common Shares

By |2020-04-06T18:24:14-04:00April 6th, 2020|News|Comments Off on Halberd Announces Agreement To Retire 192,000,000 Outstanding Common Shares

Halberd announces agreement to retire 192,000,000 outstanding common shares and acquisition/joint venture to be announced, in detail, this week. Lake Charles, Louisiana -- April 3, 2020 - Halberd Corporation (PINKSHEETS: HALB) announces that it has reached an agreement with shareholders holding 192,000,000 shares of the 482,838,125 reported as currently outstanding. Those shares will be returned to ...

Go to Top